BofA analyst Tim Anderson lowered the firm’s price target on Apogee Therapeutics (APGE) to $81 from $82 and keeps a Buy rating on the shares after the company reported Q3 results and guided to a cash runway into the second half of 2028. The firm’s revised target reflects $58 per share in value from AD, $6 per share from COPD, $6 per share from asthma, and $11 per share from net cash, the analyst noted.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics initiated with an Overweight at Stephens
- 3 ‘Strong Buy’ Stocks to Buy Today, 12/10/2025, According to Top Analysts
- Apogee Therapeutics initiated with a Buy at Deutsche Bank
- Buy Rating for Apogee Therapeutics: Strong Financials and Promising Pipeline Drive Positive Outlook
- Apogee Therapeutics Reports Q3 2025 Financial Progress